1. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 myocardial perfusion imaging.J Nucl Med 1989; 30 (3): 301–311.
2. Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, et al. Technetium-99m Tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging.J Nucl Med 1993; 34 (2): 222–227.
3. Jain D, Wackers FJ, Mattera J, McMahon M, Sinusas AJ, Zaret BL. Biokinetics of Technetium-99m tetrofosmin: Myocardial imaging agent: Implications for a one-day imaging protocol.J Nucl Med 1993; 34 (8): 1254–1259.
4. Higley B, Smith FW, Smith T, Gemmel HG, Gupta PD, Gvozdanovic DV, et al. Technetium-99m 1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent.J Nucl Med 1993; 34 (1): 30–38.
5. Gerson MC, Lukes J, Deutsch E, Biniakiewicz D, Rohe RC, Washburn LC, et al. Comparison of Technetium-99m-Q12 and Tl-201 for detection of angiographically documented coronary artery disease in humans.J Nucl Cardiol 1994; 1: (6): 1499–1508.